XenoPort Inc., which missed out on an anticipated $23 million milestone payment this quarter after partner GlaxoSmithKline plc yanked the new drug application for Solzira in restless legs syndrome (RLS) due to a filing glitch, beefed up its balance sheet with a $40 million registered direct offering. (BioWorld Today) Read More
